⏳ Fetching live dividend data...
Home › Calculator › RSLS Dividend Calculator 2026
ReShape Lifesciences Inc. · NASDAQ
Price: $3.92 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in RSLS → $1951266529.34M in 10 years · $162,294,901,526,523.75/month
Founded in 2002 and based in San Clemente, California, ReShape Lifesciences Inc. operates as a medical device company dedicated to addressing obesity and metabolic diseases. The company's market extends throughout the United States, Australia, Europe, and globally. Its diverse product lineup features the Lap-Band System, a minimally invasive, long-term solution for severe obesity that offers an alternative to more extensive surgical interventions like gastric bypass or sleeve gastrectomy. Under development is the ReShape Vest system, an investigational, minimally invasive device that is laparoscopically implanted around the stomach to assist obese and morbidly obese patients in losing weight, without cutting or permanently removing parts of the stomach or bypassing any section of the gastrointestinal tract. ReShape also supports patients through the ReShapeCare virtual health coaching program, a telehealth service aimed at promoting healthy lifestyle adjustments for individuals undergoing medically supervised weight management. Additionally, the company is conducting preclinical development for ReShape Diabetes Bloc-Stim Neuromodulation, a technology intended for the treatment of type 2 diabetes mellitus. Among its offerings is the Obalon Balloon System, a swallowable capsule used to monitor and display the balloon's exact position during its placement. The company, initially incorporated as EnteroMedics Inc., changed its name to ReShape Lifesciences Inc. in 2017.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open RSLS position with:
Real after-tax yield depends on where you live and how you hold RSLS.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 51.02% | 48.22% | $5,102 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 43.37% | 40.57% | $4,337 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 40.82% | 38.02% | $4,082 / yr |
| 🇬🇧 UK ISA | 0% | 51.02% | 48.22% | $5,102 / yr |
| 🇬🇧 UK Taxable | 8.75% | 46.56% | 43.76% | $4,656 / yr |
| 🇨🇦 TFSA | 0% | 51.02% | 48.22% | $5,102 / yr |
| 🇨🇦 CA Taxable | 25% | 38.27% | 35.47% | $3,827 / yr |
| 🇦🇺 Super (pension) | 15% | 43.37% | 40.57% | $4,337 / yr |
| 🇦🇺 AU Taxable | 30% | 35.71% | 32.91% | $3,571 / yr |
| 🇩🇪 DE Taxable | 26.375% | 37.56% | 34.76% | $3,756 / yr |
| 🇫🇷 FR Taxable | 30% | 35.71% | 32.91% | $3,571 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
RSLS pays quarterly — 4 times per year. Next ex-div: TBD.
How RSLS compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RSLS sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RSLS dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
ReShape Lifesciences Inc. (RSLS) is currently trading at $3.92, trading near its 52-week low. The current dividend yield is 51.02% based on an annual payout of $2.00 per share.
ReShape Lifesciences Inc. (RSLS) is a healthcare stock currently trading at $3.92 with a dividend yield of 51.02%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →